NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 27, 2006--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that TP10, its lead complement inhibitor, did not meet the primary endpoint in a double-blind, placebo-controlled Phase IIb study in female subjects undergoing high risk cardiac surgery utilizing cardiopulmonary bypass (CPB), thus confirming the results for female subjects in a previous TP10 trial. The objective of this female-only study was to assess the safety and ability of TP10 to reduce the incidence of death and heart attack that occurs after cardiac surgery in female patients on CPB. A previous Phase II study with TP10 in patients on CPB had demonstrated statistically significant efficacy in males but not in females, so the current study was designed to further assess the safety and efficacy of TP10 in females.
